Early prediction of median survival among a large AIDS surveillance cohort

Enanoria, Wayne T. A.; Hubbard, Alan E.; van der Laan, Mark J.; Mi Chen; Ruiz, Juan; Colford, Jr., John M.
January 2007
BMC Public Health;2007, Vol. 7, p127
Academic Journal
Background: For individuals with AIDS, data exist relatively soon after diagnosis to allow estimation of "early" survival quantiles (e.g., the 0.10, 0.15, 0.20 and 0.30 quantiles, etc.). Many years of additional observation must elapse before median survival, a summary measure of survival, can be estimated accurately. In this study, a new approach to predict AIDS median survival is presented and its accuracy tested using AIDS surveillance data. Methods: The data consisted of 96,373 individuals who were reported to the HIV/AIDS Reporting System of the California Department of Health Services Office of AIDS as of December 31, 1996. We defined cohorts based on quarter year of diagnosis (e.g., the "931" cohort consists of individuals diagnosed with AIDS in the first quarter of 1993). We used early quantiles (estimated using the Inverse Probability of Censoring Weighted estimator) of the survival distribution to estimate median survival by assuming a linear relationship between the earlier quantiles and median survival. From this model, median survival was predicted for cohorts for which a median could not be estimated empirically from the available data. This prediction was compared with the actual medians observed when using updated survival data reported at least five years later. Results: Using the 0.15 quantile as the predictor and the data available as of December 31, 1996, we were able to predict the median survival of four cohorts (933, 934, 941, and 942) to be 34, 34, 31, and 29 months. Without this approach, there were insufficient data with which to make any estimate of median survival. The actual median survival of these four cohorts (using data as of December 31, 2001) was found to be 32, 40, 46, and 80 months, suggesting that the accuracy for this approach requires a minimum of three years to elapse from diagnosis to the time an accurate prediction can be made. Conclusion: The results of this study suggest that early and accurate prediction of median survival time after AIDS diagnosis may be possible using early quantiles of the survival distribution. The methodology did not seem to work well during a period of significant change in survival as observed with highly active antiretroviral treatment, but results suggest that it may work well in a time of more gradual improvement in survival.


Related Articles

  • "Driving the devil away": qualitative insights into miraculous cures for AIDS in a rural Tanzanian ward. Roura, Maria; Nsigaye, Ray; Nhandi, Benjamin; Wamoyi, Joyce; Busza, Joanna; Urassa, Mark; Todd, Jim; Zaba, Basia // BMC Public Health;2010, Vol. 10, p427 

    Background: The role of religious beliefs in the prevention of HIV and attitudes towards the infected has received considerable attention. However, little research has been conducted on Faith Leaders' (FLs) perceptions of antiretroviral therapy (ART) in the developing world. This study...

  • Early Experiences Implementing Pre-exposure Prophylaxis (PrEP) for HIV Prevention in San Francisco. Liu, Albert; Cohen, Stephanie; Follansbee, Stephen; Cohan, Deborah; Weber, Shannon; Sachdev, Darpun; Buchbinder, Susan // PLoS Medicine;Mar2014, Vol. 11 Issue 3, p1 

    : Albert Liu and colleagues report early experiences with uptake and delivery of pre-exposure prophylaxis(PrEP)for HIV prevention in three different settings in San Francisco. PrEP can be an important component of a comprehensive HIV prevention program and can complement efforts to increase HIV...

  • The Feasibility of a Community-Based Directly Administered Antiretroviral Therapy Program. Wohl, Amy Rock; Garland, Wendy H.; Squires, Kathleen; Witt, Mallory; Larsen, Robert; Kovacs, Andrea; Hader, Shannon; Weidle, Paul J. // Clinical Infectious Diseases;6/1/2004 Supplement, Vol. 38, pS388 

    Improved treatment-adherence support programs are needed to help human immunodeficiency virus (HIV)- infected persons comply with complex highly active antiretroviral treatment (HAART) regimens. In an experimental directly administered antiretroviral therapy (DAART) program, treatment-naive and...

  • Modified Directly Observed Therapy for the Treatment of HIV--Seropositive Substance Users: Lessons Learned from a Pilot Study. Macalino, Grace E.; Mitty, Jennifer A.; Bazerman, Lauri B.; Singh, Kavita; McKenzie, Michelle; Flanigan, Timothy // Clinical Infectious Diseases;6/1/2004 Supplement, Vol. 38, pS393 

    Highly active antiretroviral therapy (HAART) can dramatically decrease human immunodeficiency virus (HIV) load in plasma, increase CD4+ cell counts, and prolong life for HIV-seropositive persons. However, the need for optimal adherence has been recognized. We implemented a pilot community-based...

  • The Role of Self-Efficacy in HIV Treatment Adherence: Validation of the HIV Treatment Adherence Self-Efficacy Scale (HIV-ASES). Johnson, Mallory O.; Neilands, Torsten B.; Dilworth, Samantha E.; Morin, Stephen F.; Remien, Robert H.; Chesney, Margaret A. // Journal of Behavioral Medicine;Oct2007, Vol. 30 Issue 5, p359 

    Adherence to HIV treatment, including adherence to antiretroviral (ART) medication regimens, is paramount in the management of HIV. Self-efficacy for treatment adherence has been identified as an important correlate of medication adherence in the treatment of HIV and other medical conditions....

  • Provision of antiretroviral treatment in conflict settings: the experience of M�decins Sans Fronti�res. O'Brien, Daniel P.; Venis, Sarah; Greig, Jane; Shanks, Leslie; Ellman, Tom; Sabapathy, Kalpana; Frigati, Lisa; Mills, Clair // Conflict & Health;2010, Vol. 4, p12 

    Introduction: Many countries ravaged by conflict have substantial morbidity and mortality attributed to HIV/AIDS yet HIV treatment is uncommonly available. Universal access to HIV care cannot be achieved unless the needs of populations in conflict-affected areas are addressed. Methods: From 2003...

  • Treating 3 million people living with HIV/AIDS by 2005.  // WHO Drug Information;2004, Vol. 18 Issue 1, p11 

    Presents news briefs related to global HIV/AIDS treatment as of 2004. World Health Organization's launching of a strategy for treating three million people with HIV/AIDS by 2005; Mechanism for expanding access to quality and effective treatment for HIV/AIDS under the AIDS medicines and...

  • Absolute Count and Percentage of CD4+ Lymphocytes Are Independent Predictors of Disease Progression in HIV-Infected Persons Initiating Highly Active Antiretroviral Therapy. Hulgan, Todd; Shepherd, Bryan E.; Raffanti, Stephen P.; Fusco, Jennifer S.; Beckerman, Robin; Barkanic, Gema; Sterling, Timothy R. // Journal of Infectious Diseases;2/1/2007, Vol. 195 Issue 3, p425 

    Background. Highly active antiretroviral therapy (HAART) is recommended when the absolute CD4+ T lymphocyte count is <200 cells/mm³, and it should be considered when that count is ⩾200, although the optimal timing when it is ⩾200 is unclear. Because preliminary data had suggested...

  • CHAPTER 54: HIV & AIDS. Miller, Richard K.; Washington, Kelli D. // Healthcare Business Market Research Handbook;2007, p240 

    Chapter 54 of the book "The 2006 Healthcare Business Market Research Handbook" is presented. It explores the prevalence of and medical expenditures associated with human immunodeficiency virus (HIV) infections and acquired immunodeficiency syndrome (AIDS) in the U.S. It highlights the decline in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics